Literature DB >> 18068174

Genetic screening of the LPL gene in hypertriglyceridaemic patients.

William T Wright1, Ian S Young, D Paul Nicholls, Colin A Graham.   

Abstract

Serum triglyceride (TG) level is an important independent risk factor for coronary heart disease, with the lipoprotein lipase (LPL) enzyme playing the major role in regulating the catabolism of TG rich lipoproteins. The complete sequence analysis of the LPL gene was carried out on 19 individuals with extreme hypertriglyceridaemia (HTG; TG>14 mmol/l) with a total of 42 sequence variants being identified, a number of which are novel to this study. A total of eight patients were shown to have functional variants (p.D36N, p.R197H, p.N318S, p.V340I) that alter amino acids at 11 of the 16 LPL alleles. Multiplex ligation-dependent probe amplification (MLPA) analysis showed no exonic deletion or duplications in this population. Further analysis of the p.N318S (also called N291S) variant identified in the sequencing screen, in larger case and control populations, identified this mutation to be strongly associated with HTG. This study has produced a more comprehensive SNP map of LPL and its surrounding area and identified p.N318S as a major predisposing factor to HTG in the Northern Irish population.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18068174     DOI: 10.1016/j.atherosclerosis.2007.10.029

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

1.  Mutations in LPL, APOC2, APOA5, GPIHBP1 and LMF1 in patients with severe hypertriglyceridaemia.

Authors:  R P Surendran; M E Visser; S Heemelaar; J Wang; J Peter; J C Defesche; J A Kuivenhoven; M Hosseini; M Péterfy; J J P Kastelein; C T Johansen; R A Hegele; E S G Stroes; G M Dallinga-Thie
Journal:  J Intern Med       Date:  2012-02-13       Impact factor: 8.989

2.  Lipoprotein lipase gene sequencing and plasma lipid profile.

Authors:  Dilek Pirim; Xingbin Wang; Zaheda H Radwan; Vipavee Niemsiri; John E Hokanson; Richard F Hamman; M Michael Barmada; F Yesim Demirci; M Ilyas Kamboh
Journal:  J Lipid Res       Date:  2013-11-09       Impact factor: 5.922

3.  Genetic and secondary causes of severe HDL deficiency and cardiovascular disease.

Authors:  Andrew S Geller; Eliana Y Polisecki; Margaret R Diffenderfer; Bela F Asztalos; Sotirios K Karathanasis; Robert A Hegele; Ernst J Schaefer
Journal:  J Lipid Res       Date:  2018-10-17       Impact factor: 5.922

4.  Resequencing of LPL in African Blacks and associations with lipoprotein-lipid levels.

Authors:  Dilek Pirim; Xingbin Wang; Zaheda H Radwan; Vipavee Niemsiri; Clareann H Bunker; M Michael Barmada; M Ilyas Kamboh; F Yesim Demirci
Journal:  Eur J Hum Genet       Date:  2015-01-28       Impact factor: 4.246

5.  Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants.

Authors:  Ursula Kassner; Bastian Salewsky; Marion Wühle-Demuth; Istvan Andras Szijarto; Thomas Grenkowitz; Priska Binner; Winfried März; Elisabeth Steinhagen-Thiessen; Ilja Demuth
Journal:  Eur J Hum Genet       Date:  2015-01-14       Impact factor: 4.246

6.  Polygenic Architecture of Common Severe Hypertriglyceridemia.

Authors:  Takashi Yamamoto; Takanari Gotoda
Journal:  J Atheroscler Thromb       Date:  2020-06-04       Impact factor: 4.928

7.  A Heterozygous LMF1 Gene Mutation (c.1523C>T), Combined With an LPL Gene Mutation (c.590G>A), Aggravates the Clinical Symptoms in Hypertriglyceridemia.

Authors:  Danxia Guo; Yingchun Zheng; Zhongzhi Gan; Yingying Guo; Sijie Jiang; Fang Yang; Fu Xiong; Hua Zheng
Journal:  Front Genet       Date:  2022-03-16       Impact factor: 4.599

8.  Identification of New Genetic Determinants in Pediatric Patients with Familial Hypercholesterolemia Using a Custom NGS Panel.

Authors:  Lena Rutkowska; Kinga Sałacińska; Dominik Salachna; Paweł Matusik; Iwona Pinkier; Łukasz Kępczyński; Małgorzata Piotrowicz; Ewa Starostecka; Andrzej Lewiński; Agnieszka Gach
Journal:  Genes (Basel)       Date:  2022-06-01       Impact factor: 4.141

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.